Biliary Atresia (BA) - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: BF24F351DF07EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Biliary Atresia (BA) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Biliary Atresia (BA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Biliary Atresia (BA) Understanding

The DelveInsight Biliary Atresia (BA) epidemiology report gives a thorough understanding of the Biliary Atresia (BA) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Biliary Atresia (BA) in the US, Europe, and Japan. The report covers the detailed information of the Biliary Atresia (BA) epidemiology scenario in seven major countries (US, EU5, and Japan).

Biliary Atresia (BA) Epidemiology Perspective by DelveInsight

The Biliary Atresia (BA) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Biliary Atresia (BA) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Biliary Atresia (BA) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Biliary Atresia (BA) Detailed Epidemiology Segmentation

The Biliary Atresia (BA) epidemiology covered in the report provides historical as well as forecasted Biliary Atresia (BA) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Biliary Atresia (BA) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Biliary Atresia (BA) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Biliary Atresia (BA) Epidemiology Report and Model provide an overview of the global trends of Biliary Atresia (BA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Biliary Atresia (BA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Biliary Atresia (BA)
• The report provides the segmentation of the Biliary Atresia (BA) epidemiology

Report Highlights

• 11-year Forecast of Biliary Atresia (BA) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Biliary Atresia (BA)
• Cases of Biliary Atresia (BA) by Mutation Types
• Biliary Atresia (BA) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Biliary Atresia (BA)?
• What are the key findings pertaining to the Biliary Atresia (BA) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Biliary Atresia (BA) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Biliary Atresia (BA)?
• What are the currently available treatments of Biliary Atresia (BA)?

Reasons to buy

The Biliary Atresia (BA) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Biliary Atresia (BA) market
• Quantify patient populations in the global Biliary Atresia (BA) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Biliary Atresia (BA) therapeutics in each of the markets covered
• Understand the magnitude of Biliary Atresia (BA) population by its epidemiology
• The Biliary Atresia (BA) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF BILIARY ATRESIA (BA)

3. BILIARY ATRESIA (BA): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Biliary Atresia (BA) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Biliary Atresia (BA) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Biliary Atresia (BA) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Biliary Atresia (BA) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Biliary Atresia (BA) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Biliary Atresia (BA) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Biliary Atresia (BA) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Biliary Atresia (BA) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Biliary Atresia (BA) Treatment and Management
6.2. Biliary Atresia (BA) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Biliary Atresia (BA) Epidemiology in 7MM (2019-2032)
Table 2: Biliary Atresia (BA) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Biliary Atresia (BA) Epidemiology in the United States (2019-2032)
Table 4: Biliary Atresia (BA) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Biliary Atresia (BA) Epidemiology in Germany (2019-2032)
Table 6: Biliary Atresia (BA) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Biliary Atresia (BA) Epidemiology in France (2019-2032)
Table 8: Biliary Atresia (BA) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Biliary Atresia (BA) Epidemiology in Italy (2019-2032)
Table 10: Biliary Atresia (BA) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Biliary Atresia (BA) Epidemiology in Spain (2019-2032)
Table 12: Biliary Atresia (BA) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Biliary Atresia (BA) Epidemiology in the United Kingdom (2019-2032)
Table 14: Biliary Atresia (BA) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Biliary Atresia (BA) Epidemiology in Japan (2019-2032)
Table 16: Biliary Atresia (BA) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Biliary Atresia (BA) Epidemiology in 7MM (2019-2032)
Figure 2 Biliary Atresia (BA) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Biliary Atresia (BA) Epidemiology in the United States (2019-2032)
Figure 4 Biliary Atresia (BA) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Biliary Atresia (BA) Epidemiology in Germany (2019-2032)
Figure 6 Biliary Atresia (BA) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Biliary Atresia (BA) Epidemiology in France (2019-2032)
Figure 8 Biliary Atresia (BA) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Biliary Atresia (BA) Epidemiology in Italy (2019-2032)
Figure 10 Biliary Atresia (BA) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Biliary Atresia (BA) Epidemiology in Spain (2019-2032)
Figure 12 Biliary Atresia (BA) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Biliary Atresia (BA) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Biliary Atresia (BA) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Biliary Atresia (BA) Epidemiology in Japan (2019-2032)
Figure 16 Biliary Atresia (BA) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report